{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:08:59Z","timestamp":1792760939005,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ahj.2020.01.007","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T11:14:18Z","timestamp":1579259658000},"page":"157-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib"],"prefix":"10.1016","volume":"222","author":[{"given":"Jean-Claude","family":"Tardif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David D.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mooser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Heinonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Guertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2020.01.007_bb0005","unstructured":"World Health Organization. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)"},{"key":"10.1016\/j.ahj.2020.01.007_bb0010","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.01.007_bb0015","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.01.007_bb0020","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.01.007_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728214.2017.1269743","article-title":"Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis","volume":"22","author":"Bertrand","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ahj.2020.01.007_bb0030","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","article-title":"Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges","volume":"128","author":"Rosenson","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.01.007_bb0035","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.01.007_bb0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/ATVBAHA.116.307122","article-title":"CETP: Pharmacogenomics-based response to the CETP inhibitor dalcetrapib","volume":"37","author":"Tardif","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2020.01.007_bb0045","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCGENETICS.114.000663","article-title":"Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib","volume":"8","author":"Tardif","year":"2015","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ahj.2020.01.007_bb0050","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/CIRCGENETICS.116.001405","article-title":"Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: Concordance with clinical outcomes","volume":"9","author":"Tardif","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ahj.2020.01.007_bb0055","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1161\/CIRCULATIONAHA.117.031134","article-title":"ADCY9 (adenylate cyclase type 9) inactivation protects from atherosclerosis only in the absence of CETP (cholesteryl ester transfer protein)","volume":"138","author":"Rautureau","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.01.007_bb0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamacardio.2018.0569","article-title":"ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in Patients with high-risk vascular disease: A nested case-control study","volume":"3","author":"Nissen","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2020.01.007_bb0065","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamacardio.2018.2379","article-title":"Randomized clinical trial needed to confirm whether dalcetrapib improves outcomes for specific ADCY9 genotype","volume":"3","author":"Pfeffer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ahj.2020.01.007_bb0070","doi-asserted-by":"crossref","unstructured":"Holmes MV, Smith GD. CETP inhibition and ADCY9 genotype: evidence of a qualitative pharmacogenetic interaction in cardiovascular disease? bioRxiv June 6 2018. doi: https:\/\/doi.org\/10.1101\/336875","DOI":"10.1101\/336875"},{"key":"10.1016\/j.ahj.2020.01.007_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.119.041546","article-title":"Impact of ADCY9 genotype on response to anacetrapib","author":"Hopewell","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2020.01.007_bb0080","doi-asserted-by":"crossref","unstructured":"HPS3\/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017;377:1217-122. doi: 10.1056\/NEJMoa1706444.","DOI":"10.1056\/NEJMoa1706444"},{"key":"10.1016\/j.ahj.2020.01.007_bb0085","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1194\/jlr.M068940","article-title":"Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys","volume":"58","author":"Brodeur","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ahj.2020.01.007_bb0090","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/ATVBAHA.115.306680","article-title":"Cholesteryl ester transfer protein inhibition with anacetrapib decreases fractional clearance rates of high-density lipoprotein apolipoprotein A-I and plasma cholesteryl ester transfer protein","volume":"36","author":"Reyes-Soffer","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2020.01.007_bb0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1194\/jlr.M300198-JLR200","article-title":"Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency","volume":"45","author":"Asztalos","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.ahj.2020.01.007_bb0100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/MOL.0b013e3283475e00","article-title":"Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism","volume":"22","author":"Niesor","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.ahj.2020.01.007_bb0105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/fca.12.25","article-title":"An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels","volume":"8","author":"Rhainds","year":"2012","journal-title":"Futur Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320300211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320300211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:04:52Z","timestamp":1757570692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320300211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":21,"alternative-id":["S0002870320300211"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.01.007","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}